anti-infective drugs
PreclinicalSmall molecule
anti-infective drugs is one of 21 small molecule programs targeting Infectious Disease. It is currently in Preclinical.
1
Indications
4
Total Trials
3
Active Trials
20
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
28 competitors in Infectious Disease
#DrugCompanyPhaseTrials
1Cipro
BayerApproved
Maxipime
PfizerApproved
Calquence
AstraZenecaApproved
Merrem
BB. Braun Medical Inc.
Approved
Peridex
DDexcel Pharma Technologies Ltd.
Approved
Amoxil
GGlobal Antibiotics Research and Development Partnership
Approved
Zithromax
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Aciphex
Akero TherapeuticsApproved
Lampit
BayerPhase 3
Riboflavin
CCornea and Laser Eye Institute
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Infectious Disease1 trial
Population Pharmacokinetics of Meropenem and Linezolid in Children With Severe Infectious Diseases
Unknown status·—··NCT03643497·800 enrolled
Infections1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for anti-infective drugs. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- SShandong University